Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial).
J Support Oncol., 9(1):32-40 (2011)
A retrospective study to evaluate the work-up and follow-up of patients with monoclonal gammopathy of undetermined significance.
Clin Lymphoma Myeloma Leuk., Aug;11(4):336-41 (2011)
Metatarsal stress fractures in patients with multiple myeloma treated with long-term bisphosphonates: a report of six cases.
J Bone Joint Surg Am., Sep;93(18):e106 (2011)
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Br. J. Haematol., Dec;155(5):580-7 (2011)
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Clin. Cancer Res., Feb;15(3):1069-75 (2009)
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
Blood., Feb;113(9):1992-2002 (2009)
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Nat Rev Clin Oncol., May;6(5):255-6 (2009)
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Br. J. Haematol., Feb;148(4):569-81 (2010)
Monoclonal gammopathy of undetermined significance: a consensus statement.
Br. J. Haematol., Jul;150(1):28-38 (2010)
A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay.
Int. J. Oncol., Jul;37(1):71-9 (2010)
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Br. J. Haematol., Aug;138(4):467-78 (2007)
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Am. J. Hematol., Jan;86(1):25-30 (2011)
Using a powered bone marrow biopsy system results in shorter procedures, causes less residual pain to adult patients, and yields larger specimens.
Diagn Pathol., 6:23 (2011)
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.
Blood., Jul;110(1):287-95 (2007)
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Ann. Hematol., Aug;87(8):623-31 (2008)
NF-kappaB in the pathogenesis and treatment of multiple myeloma.
Curr. Opin. Hematol., Jul;15(4):391-9 (2008)
Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
Urology., May;73(5):1119-25 (2009)
New drugs in multiple myeloma.
Curr Opin Support Palliat Care., Sep;2(3):204-10 (2008)
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
Clin. Cancer Res., Oct;14(19):6289-95 (2008)
Myeloma bone disease.
Best Pract Res Clin Haematol., 18(4):653-72 (2005)